on 22/04/2008 12:32

BioAlliance Pharma announces preliminary results from the pivotal US phase III trial for Loramyc™
Read more

on 09/01/2008 17:47

BioAlliance Pharma receives market approval for Loramyc® in the United Kingdom and Denmark
Read more

on 05/12/2007 17:19

BioAlliance Pharma acquires the European commercialization rights to pafuramidine for the treatment of Pneumocystis carinii pneumonia. Building a consistent product portfolio in opportunistic infections in cancer and AIDS patients
Read more

on 28/11/2007 17:15

BioAlliance Pharma accelerates its international clinical research program Extension to the United States of the acyclovir Lauriad® Phase III trial
Read more

on 26/07/2007 17:10

BioAlliance Pharma announces fund raising of € 40 million by private placement. This operation will foster an accelerated growth of the company
Read more